MAR 11, 2014
ThromboGenics NV has been awarded a €3 million grant from the Flemish government agency for Innovation by Science and Technology (IWT) to research potential new biotherapeutics designed to reduce the vascular leakage and inflammation associated with diabetic macular edema (DME).
ThromboGenics intends to use the grant to learn more about the role of a novel pathway believed to play an important role in the development of DME by modulating vascular leakage and inflammation.
A key part of the grant funded work will develop new in vitro assays and in vivo models to identify biotherapeutics which activate the pathway. This will allow the company to identify preclinical candidates that meet a target product profile based around in vitro potency, in vivo efficacy and drug-like properties. ThromboGenics expects to leverage the AMP-Rx protein design technology which the company licensed from Eleven Biotherapeutics in May 2013.